EUVIMEDEUVIMED entdecken
Open Access

Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction

Maryam Jamal AlSaeed iD, Cameron D Thomas iD, Francesco Franchi iD, Ellen C Keeley iD, Julio D Duarte iD, Yan Gong iD, Joseph S Rossi iD, Amber L Beitelshees iD, George A Stouffer, Craig R Lee iD, Dominick J Angiolillo iD, Larisa H Cavallari iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Maryam Jamal AlSaeed und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of F…. Hauptthemen laut MEDLINE: Clopidogrel, Glomerular Filtration Rate, Cytochrome P-450 CYP2C19, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NHGRI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ABCD‐GENE score was developed to predict poor response to clopidogrel and includes A ge, B ody mass index, C hronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m 2 ), D iabetes, and CYP2C19 GENE variants; a score ≥ 10 is predictive of reduced clopidogrel effectiveness after percutaneous coronary intervention (PCI). Estimation of GFR without a race variable via the CKD‐EPI Scr 2021 equation is now recommended. We examined the impact of using the CKD‐EPI Scr 2021 vs. 2009 equation on the ABCD‐GENE score for post‐PCI patients. A total of 4335 adult patients ( n = 925 Black) who underwent PCI and CYP2C19 genotyping were included, with GFR estimated for each patient via the CKD‐EPI Scr 2021 and CKD‐EPI 2009 equations. The ABCD‐GENE score, calculated based on each GFR estimation, was compared. With the CKD‐EPI Scr 2021 vs. 2009 equation, median (IQR) eGFR was lower (74 [55–94] vs. 81 [60–103] mL/min/1.73 m 2 , P < 0.001), and CKD prevalence was higher (31% vs. 25%, P < 0.001) among Black patients, whereas eGFR was higher (85 [65–99] vs. 80 [61–94] mL/min/1.73m 2 , P < 0.001), and CKD prevalence was lower (20% vs. 24%, P < 0.001) in non‐Black patients. This led to 12 (1%) Black patients being reclassified from low to high risk of poor clopidogrel response and 30 (1%) non‐Black patients being recategorized from high to low risk ( P < 0.001 for both comparisons). Removal of the race variable from GFR estimation significantly impacted the prediction of clopidogrel effectiveness via the ABCD‐GENE score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelGlomerular Filtration RateCytochrome P-450 CYP2C19Renal Insufficiency, ChronicPlatelet Aggregation InhibitorsHumansMaleFemaleMiddle AgedAgedPercutaneous Coronary InterventionGenotypeBody Mass IndexAge Factors

Substanzen

ClopidogrelCytochrome P-450 CYP2C19CYP2C19 protein, humanPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al Hofuf, Saudi Arabia.
  • Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville, University of Florida, Jacksonville, Florida, USA.
  • Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Division of Cardiology and McAllister Heart Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Maryam Jamal AlSaeed, Cameron D Thomas, Francesco Franchi, Ellen C Keeley, Julio D Duarte, Yan Gong, Joseph S Rossi, Amber L Beitelshees, Craig R Lee, Dominick J Angiolillo, Larisa H Cavallari

Förderung

  • NHLBI NIH HHS
  • NHGRI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Human Genome Research Institute

Zitieren

APA

AlSaeed, M. J., Thomas, C. D., Franchi, F., Keeley, E. C., Duarte, J. D., Gong, Y., Rossi, J. S., Beitelshees, A. L., Stouffer, G. A., Lee, C. R., Angiolillo, D. J., & Cavallari, L. H. (2024). Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3385

Vancouver

AlSaeed MJ, Thomas CD, Franchi F, Keeley EC, Duarte JD, Gong Y, et al. Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3385

BibTeX
@article{AlSaeed2024,
  author = {AlSaeed, Maryam Jamal and Thomas, Cameron D and Franchi, Francesco and Keeley, Ellen C and Duarte, Julio D and Gong, Yan and Rossi, Joseph S and Beitelshees, Amber L and Stouffer, George A and Lee, Craig R and Angiolillo, Dominick J and Cavallari, Larisa H},
  title = {Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3385}
}
Kostenlos starten →